Actively Recruiting
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
Led by First Affiliated Hospital, Sun Yat-Sen University · Updated on 2026-04-08
116
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.
CONDITIONS
Official Title
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years with primary membranous nephropathy
- Receiving maximum tolerated dose of ACEI/ARB for at least 4 weeks
- Blood pressure at or below 140/90 mmHg
- Urine protein content between 1.0 and 5.0 g/day
- Estimated glomerular filtration rate (eGFR) of 60 or higher (CKD-EPI method)
- Women must be postmenopausal, postoperatively infertile, or using medical contraception
- Voluntary signing of informed consent
You will not qualify if you...
- Diagnosis of type 1 or type 2 diabetes, except recent steroid-induced diabetes with no evidence of secondary diabetic nephropathy within 6 months
- Secondary membranous nephropathy caused by hepatitis B or C, lupus, drug therapy, cancer, or other causes
- Uncontrolled high blood pressure
- Treatment with glucocorticoids, immunosuppressants, or biological agents in the past 6 months
- Treatment with any other study drug within the last month
- Females who are pregnant, lactating, or planning pregnancy within 24 months
- Female or male patients unwilling to use contraceptives during the study
- History of mental illness
- Laboratory abnormalities: hemoglobin below 80 g/L, platelet count below 80 x10^9/L, neutrophil count below 1.0 x10^9/L, or liver enzymes (AST or ALT) more than 2.5 times the normal limit
- Life-threatening nephrotic syndrome or unexplained rapid kidney function decline
- Unsuitable for the trial as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wei Chen
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
W
Wei Chen
CONTACT
Q
Qiong Wen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here